-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
Context Therapeutics And 3 Other Stocks Under $1 Insiders Are Aggressively Buying
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
Theriva Biologics
- The Trade: Theriva Biologics, Inc. (NYSE:TOVX) CEO and CFO Steven A Shallcross bought a total of 25,000 shares at an average price of $0.75. To acquire these shares, it cost around $18.7 thousand.
- What's Happening: Theriva Biologics received a notice of allowance for its U.S. patent application 16/982,211 titled "Alkaline Phosphatase Agents For Treatment Of Radiation Disorders."
- What Theriva Biologics Does: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs.
United States Antimony
- The Trade: United States Antimony Corporation (NYSE:UAMY) Director Lloyd Bardswich acquired a total of 10,000 shares at an average price of $0.44. The insider spent around $4.4 thousand to buy those shares.
- What's Happening: On Nov. 21, 2022, United States Antimony's board approved a 5 million share stock buy back.
- What United States Antimony Does: United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company.
Check This Out: 5 Most Expensive Consumer Stocks You Should Worry About
Context Therapeutics
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,839 shares at an average price of $0.72. To acquire these shares, it cost around $4.9 thousand.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
Don't forget to check out our premarket coverage here
Precipio
- The Trade: Precipio, Inc. (NASDAQ:PRPO) Director Sandberg Richard acquired a total of 20,000 shares at an average price of $0.78. The insider spent $15.53 thousand to buy those shares.
- What's Happening: Precipio signed another major hemescreen customer for $650k per year.
- What Precipio Does: Precipio Inc is a healthcare solutions company focused on cancer diagnostics.
The Dow Jones closed higher by more than 250 points on Monday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道琼斯指数周一收盘上涨超过250点。当内部人士购买或出售股票时,这表明他们对公司前景的信心或担忧。对细价股感兴趣的投资者和交易者可以将其视为影响其整体投资或交易决策的一个因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是近期一些值得注意的细价股内幕交易。欲了解更多,请查看 本辛加的内幕交易 平台。
Theriva Biologics
Theriva 生物制剂
- The Trade: Theriva Biologics, Inc. (NYSE:TOVX) CEO and CFO Steven A Shallcross bought a total of 25,000 shares at an average price of $0.75. To acquire these shares, it cost around $18.7 thousand.
- What's Happening: Theriva Biologics received a notice of allowance for its U.S. patent application 16/982,211 titled "Alkaline Phosphatase Agents For Treatment Of Radiation Disorders."
- What Theriva Biologics Does: Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs.
- 交易: Theriva Biologics, Inc. 纽约证券交易所代码:TOVX)首席执行官兼首席财务官 Steven A Shallcross 共购买了 25,000 股股票 平均价格为0.75美元。收购这些股票的成本约为18.7万美元。
- 发生了什么: Theriva Biologics收到了美国专利申请16/982,211的许可通知,该专利的标题为 “用于治疗放射性疾病的碱性磷酸酶药物”。
- Theriva Biologics 的作用: Theriva Biologics Inc是一家临床阶段的制药公司,正在开发一种新的溶瘤腺病毒(OV)平台,以应对需求未得到满足的毁灭性癌症。
United States Antimony
美国锑
- The Trade: United States Antimony Corporation (NYSE:UAMY) Director Lloyd Bardswich acquired a total of 10,000 shares at an average price of $0.44. The insider spent around $4.4 thousand to buy those shares.
- What's Happening: On Nov. 21, 2022, United States Antimony's board approved a 5 million share stock buy back.
- What United States Antimony Does: United States Antimony Corp is a fully integrated mining, transportation, milling, smelting, and selling company.
- 这笔交易: 美国锑公司 (纽约证券交易所代码:UAMY)导演劳埃德·巴德斯威奇 共收购了 10,000 股股票 平均价格为0.44美元。知情人士花了大约4.4万美元购买了这些股票。
- 发生了什么: 2022年11月21日,美国锑董事会批准了500万股股票的回购。
- 美国锑是做什么的: 美国锑公司是一家完全集采矿、运输、制粉、冶炼和销售于一体的公司。
Check This Out: 5 Most Expensive Consumer Stocks You Should Worry About
看看这个: 你应该担心的 5 只最昂贵的消费股
Context Therapeutics
情境疗法
- The Trade: Context Therapeutics Inc. (NASDAQ:CNTX) CEO Martin Lehr acquired a total of 6,839 shares at an average price of $0.72. To acquire these shares, it cost around $4.9 thousand.
- What's Happening: Context Therapeutics and Lonza recently announced that the companies are collaborating to manufacture CTIM-76, Context's clinical development candidate.
- What Context Therapeutics Does: Context Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to improving the lives of women living with cancer.
- 这笔交易: Context Therape 纳斯达克股票代码:CNTX)首席执行官马丁·莱尔 共收购了 6,839 股股份 平均价格为0.72美元。收购这些股票的成本约为4.9万美元。
- 发生了什么: Context Therapeutics和Lonza最近宣布,两家公司正在合作生产Context的临床开发候选药物 CTIM-76。
- 情境疗法是做什么的: Context Therapeutics Inc是一家处于临床阶段的生物制药公司,致力于改善癌症女性的生活。
Don't forget to check out our premarket coverage here
别忘了在这里查看我们的上市前报道
Precipio
普雷西皮奥
- The Trade: Precipio, Inc. (NASDAQ:PRPO) Director Sandberg Richard acquired a total of 20,000 shares at an average price of $0.78. The insider spent $15.53 thousand to buy those shares.
- What's Happening: Precipio signed another major hemescreen customer for $650k per year.
- What Precipio Does: Precipio Inc is a healthcare solutions company focused on cancer diagnostics.
- 这笔交易: Precipio, Inc. 纳斯达克股票代码:PRPO)导演桑德伯格·理查德 共收购了2万股股票 平均价格为0.78美元。知情人士花了15.53万美元购买了这些股票。
- 发生了什么: Precipio以每年65万美元的价格签下了另一位主要的hemescreen客户。
- Precipio 做了: Precipio Inc是一家专注于癌症诊断的医疗保健解决方案公司。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧